THE UBIQUITOUS DISTRIBUTION OF ET-1 AND ITS RECEPTORS IMPLICATES ITS INVOLVEMENT IN A WIDE VARIETY OF PHYSIOLOGIC AND PATHOLOGIC PROCESSES IN THE BODY.

 Cardiovascular diseases are the number one cause of death globally and one of the costliest diseases for health care systems 

• atherosclerosis
• cardiac hypertrophy
• ischemic heart disease
• heart failure
• stroke

 ~10% of the world population suffers from chronic kidney disease, majority in developing world unable to afford treatment - Every year there are ~1 million deaths from untreated kidney disease

Type-1  diabetes is a metabolic disorder characterized by high blood sugar levels over a prolonged period.  If left untreated, diabetes can cause many complications. Acute complications can include diabetic ketoacidosis, hyperosmolar hyperglycemic state, or death. Serious long-term complications include cardiovascular disease, stroke, chronic kidney disease, foot ulcers, and damage to the eyes.  

Currently available therapies are mainly limited to insulin and glucose control medications. However most of the fatalities and the healthcare costs related to diabetes are from complications like heart and kidney disease. ET-traps  helps bring heart and kidney function to non disease levels.

The ET-traps approach to diabetes provides therapeutic synergy for (i) bringing back the pathologically elevated levels of endothelin-1 and (ii) repair of damage caused to the vital organs (long-term complications).

Diabetes is more than just high glucose. Click here to find out more. 

We established our PoC in the Type-1 diabetes disease space. However, elevated/ pathological levels of endothelin-1 are also found in other diseases

• Alzheimer's disease
• Multiple sclerosis
• Parkinson's disease